Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
halofuginone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5553 | 55837-20-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D003049 | Coccidiostats |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D006131 | Growth Inhibitors |
| MeSH PA | D006133 | Growth Substances |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| MeSH PA | D020533 | Angiogenesis Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Chickens | Prevention of coccidiosis caused by Eimeria tenella | Indication |
| Chickens | Prevention of coccidiosis caused by E necatrix | Indication |
| Chickens | Prevention of coccidiosis caused by E acervulina | Indication |
| Chickens | Prevention of coccidiosis caused by E maxima | Indication |
| Chickens | Prevention of coccidiosis caused by E mivati | Indication |
| Chickens | Prevention of coccidiosis caused by E brunetti | Indication |
| Turkeys | Prevention of coccidiosis caused by Eimeria adenoeides | Indication |
| Turkeys | Prevention of coccidiosis caused by E meleagrimitis | Indication |
| Turkeys | Prevention of coccidiosis caused by E gallopavonis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Stenorol | Huvepharma EOOD | 1 |
| Flavomycin / Stenorol | Huvepharma EOOD | 2 |
| BMD / Stenorol | Huvepharma EOOD | 2 |
| Stenorol Type A Medicated Article | Huvepharma EOOD | 1 |
| Flavomycin / Stenorol | Huvepharma EOOD | 2 |
| BMD / Stenorol | Huvepharma EOOD | 2 |
| Stenorol and LINCOMIX | Huvepharma EOOD | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Nuclear factor erythroid 2-related factor 2 | Transcription factor | IC50 | 7.65 | CHEMBL | |||||
| Proline--tRNA ligase, PfPRS, EC 6.1.1.15 | Enzyme | EC50 | 9.07 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| CHEBI:749217 | CHEBI |
| HFG | PDB_CHEM_ID |
| CHEMBL1197091 | ChEMBL_ID |
| CHEMBL1199540 | ChEMBL_ID |
| C010176 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10153 | IUPHAR_LIGAND_ID |
| DB04866 | DRUGBANK_ID |
| 96157002 | SNOMEDCT_US |
| C0062095 | UMLSCUI |
| CHEMBL1162013 | ChEMBL_ID |
| CHEMBL559362 | ChEMBL_ID |
| 3676 | INN_ID |
| 64924-67-0 | SECONDARY_CAS_RN |
| D08034 | KEGG_DRUG |
| 456390 | PUBCHEM_CID |
| L31MM1385E | UNII |
| L31MM1385E | INXIGHT DRUGS |
Pharmaceutical products:
None